DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Materials
Published
02 Feb 25
Updated
03 Sep 26
Views
208
Not Invested
SymriseSY1
SY1 logo
Fair Value
€98.63
Share price03 Sep
€87.211.6% undervalued intrinsic discount
Loading
1Y8.65%
7D-3.54%

Elevated Sector Risks Will Shape Industry Outlook Amid Global Expansion

AN
AnalystConsensusTarget
AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
02 Feb 25
Updated
03 Sep 26
Views
208
Not Invested
Fair Value€98.63
Share price€87.2
11.6% undervalued intrinsic discount
Narrative
Updates28

Last Update 03 Sep 26

Fair value Increased 3.39%

SY1: Pet Segment Momentum And Pricing Power Shifts Will Shape Future Repricing

Analysts have raised the Symrise fair value estimate from €95.39 to €98.63, citing higher price targets, including Jefferies' increase to €110, and supportive sector views that emphasize improving growth assumptions, particularly in pet-related activities, despite mixed rating actions across the coverage.

Analyst Commentary

Recent research on Symrise shows a split between bullish analysts who see upside in specific growth drivers and more cautious views that focus on sector risks and execution against current expectations. These views feed directly into how investors may think about valuation, growth durability, and the balance of risk and reward.

Bullish Takeaways

  • Bullish analysts highlight inflecting growth in pet related activities as a key support for Symrise, which they see as an important contributor to the higher price targets around €98 to €110.
  • Supportive sector views within ingredients are seen as backing the idea that Symrise can justify a fair value estimate close to the upper end of current analyst targets, provided it delivers on growth in its core segments.
  • The move from a lower price target of €80 to €110 by one bullish house signals confidence that Symrise can execute on its growth plans sufficiently to meet higher earnings expectations embedded in these valuations.
  • An Overweight stance with a price target near the current fair value estimate suggests some analysts see the risk and reward as acceptable, even if upside is framed more around steady execution than aggressive expansion.

Bearish Takeaways

  • Bearish analysts point to sector rotation and a slowdown in growth across ingredients stocks, which they argue has contributed to recent underperformance and may limit how much of a premium Symrise can command.
  • A Neutral stance at a price target of €79 indicates concern that current prices and fair value estimates may already reflect much of the expected growth, leaving less room for error in execution.
  • Cautious views reference a new inflation cycle with weaker demand and higher input cost pressure, which could compress margins if Symrise is unable to sustain pricing, especially versus peers with stronger perceived pricing power.
  • The shift in preference at Goldman Sachs towards stocks seen as more defensive on pricing highlights a risk that Symrise may be viewed as less protected if cost or demand pressures persist, which can cap valuation multiples even if the long term growth story remains intact.

What’s in the News for Symrise

  • No recent Symrise specific news items are available from the provided primary sources at this time.
  • No periodical coverage has been supplied in the secondary sources for Symrise for this period.
  • No additional key developments for Symrise have been provided beyond the analyst commentary already discussed.

Valuation Changes for Symrise

  • Fair Value has risen modestly from €95.39 to €98.63. This reflects a small uplift in the central valuation point used for Symrise.
  • The Discount Rate has moved slightly higher from 5.56% to 5.69%. This implies a marginally higher required return being applied to future cash flows.
  • The Revenue Growth assumption has edged up from 4.73% to 4.94%. This indicates a small adjustment to expected € sales growth for Symrise.
  • The Net Profit Margin has eased slightly from 11.53% to 11.47%. This points to a very small reduction in the projected share of € earnings retained from each euro of revenue.
  • The future P/E multiple has increased from 22.24x to 23.06x. This suggests a somewhat higher valuation being applied to Symrise earnings in the forward assumptions.
Read more
2 viewsusers have viewed this narrative update

Key Takeaways

  • Operational efficiency initiatives, portfolio optimization, and disciplined cost controls are driving lasting margin improvement, free cash flow, and overall earnings quality.
  • Focus on R&D, natural ingredient innovation, and emerging market expansion positions Symrise for premium pricing and resilient, above-market long-term growth.
  • Competitive pressures, macroeconomic headwinds, and weaker end-market demand are likely to constrain growth and margins despite cost-saving and transformation initiatives.

Catalysts

About Symrise
    Operates as a supplier of fragrances, flavorings, cosmetic base materials and active ingredients, and functional ingredients and solutions in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America.
What are the underlying business or industry changes driving this perspective?
  • Symrise is executing a multi-year transformation focused on operational efficiency, portfolio optimization, and disciplined cost management, which is already yielding substantial margin improvements (notably, a gross margin increase of 250 bps and an EBITDA margin uplift), laying the groundwork for structurally higher net margins and improved earnings compounding.
  • Ongoing and targeted cost savings measures (€40 million in 2025, following €50 million in 2024) and optimized procurement strategies are expected to deliver sustainable operating leverage and support both margin expansion and stronger free cash flow generation.
  • Symrise's continued investment in R&D, innovation, and proprietary launches in natural and functional ingredients targets growing consumer demand for health-conscious, sustainable, and science-backed solutions, positioning the firm to capture secular volume growth and premium pricing, directly benefiting revenue and margins over the long term.
  • Expansion in high-growth emerging markets such as Latin America and Asia Pacific, alongside a proactive approach to portfolio management (divestments of non-core, lower-margin businesses), is expected to boost top-line growth, increase geographic diversification, and strengthen resilience against developed market stagnation.
  • As global customers increasingly outsource ingredient complexity due to rising demand for product innovation, personalization, and regulatory-driven reformulations, Symrise's specialty expertise and enhanced customer relationships are likely to translate into above-market revenue growth and defend against commoditization risks.
Symrise Earnings and Revenue Growth

Symrise Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Symrise's revenue will grow by 4.9% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 5.0% today to 11.5% in 3 years time.
  • Analysts expect earnings to reach €651.3 million (and earnings per share of €4.64) by about September 2029, up from €246.1 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.2x on those 2029 earnings, down from 51.0x today. This future PE is greater than the current PE for the GB Chemicals industry at 22.0x.
  • Analysts expect the number of shares outstanding to decline by 1.85% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 5.69%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • The company is experiencing a normalization and slowdown in several key end markets, notably in Pet Nutrition and Pet Food, due to cautious consumer sentiment and price pressures, which may dampen segment revenue growth and compress net margins in the near to mid-term.
  • Management has revised down its organic growth guidance for 2025 from 5%-7% to 2%-5%, reflecting a more challenging global demand environment and slower market growth expectations; sustained slower growth could limit revenue and earnings upside potential.
  • Increasing regional and local competition, particularly in pet and nutrition markets, as well as pressure from private label brands, could erode Symrise's pricing power and market share, resulting in pressured revenues and potentially lower net margins.
  • Currency headwinds and macroeconomic uncertainty in regions like North America have resulted in negative FX impacts and weaker organic growth, highlighting ongoing exposure to global economic and political volatility that could impact overall earnings and free cash flow.
  • The company's transformation and cost savings initiatives, while driving margin improvement, also require reinvestment into digitalization, R&D, and organizational change, which introduces execution risk and could put pressure on near-term margins if savings do not sufficiently offset increased investment or if efficiency gains are not fully realized.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of €98.63 for Symrise based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €110.0, and the most bearish reporting a price target of just €75.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €5.7 billion, earnings will come to €651.3 million, and it would be trading on a PE ratio of 23.2x, assuming you use a discount rate of 5.7%.
  • Given the current share price of €91.82, the analyst price target of €98.63 is 6.9% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Symrise?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

SY1 logo
Symrise
20.7% undervalued intrinsic discount

Pet Care And ONE SYM Transformation Will Drive Long-Term Market Outperformance

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 22 Jul
Read Narrative
SY1 logo
Symrise
16.3% overvalued intrinsic discount

Cost Savings And Pet Nutrition Trends Will Shape Future Earnings Trajectory

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 8 Jul
Read Narrative

Fair Value vs Share Price

€98.63
vs €87.211.6% undervalued intrinsic discount
PastFuture06b2015201820212024202620272029Revenue €5.7bEarnings €651.3m
4.9%
Revenue growth
11.5%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Symrise

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Excellent balance sheet average dividend payer.

Market cap€11.9b
PB3.2x
Estimated Growth4.8%
Dividend Yield1.4%
Full analysis

CEO & management

Jean-Yves Parisot
CEO
3.6yrs
CEO Tenure

Operates as a supplier of fragrances, flavorings, cosmetic base materials and active ingredients, and functional ingredients and solutions in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide